Hash- Now 7 years old and more has come out but here is a review we did. https://t.co/uI7I5Arp9L While there is multiple RCTs, one of the main reasons brachy is rarely used and I caution its use is major evidence gaps as outlined in the paper. EBRT h…
RT @DrAndrewLoblaw: Protons main benefit is for improving RVUs not patient outcomes (at least for #ProstateCancer). From a cost-effective…
Protons main benefit is for improving RVUs not patient outcomes (at least for #ProstateCancer). From a cost-effectiveness view, #SBRT wins in 🇨🇦 Remember it’s not “charge” or “reimbursement rate” effectiveness (something lost on most CE authors)
@DrSpratticus @AmarUKishan A tad unfair to brachy. Your group ably reviewed the ample brachy RCT trial evidence and, at this very ASTRO, there was an excellent report out of HDR vs LDR trial. Certainly agree with your take on proton. @DrAndrewLoblaw @…